康复龙结构式
|
常用名 | 康复龙 | 英文名 | Oxymetholone |
---|---|---|---|---|
CAS号 | 434-07-1 | 分子量 | 332.477 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 465.9±45.0 °C at 760 mmHg | |
分子式 | C21H32O3 | 熔点 | 172-180°C | |
MSDS | 中文版 美版 | 闪点 | 249.7±25.2 °C | |
符号 |
GHS08 |
信号词 | Warning |
康复龙用途康力龙的中间体。本身为蛋白同化激素类药物,能促进蛋白质合成和抑制蛋白质异生,并能降低血胆固醇、减少钙磷排泄和减轻骨髓抑制,促进发育,促进组织新生和肉芽形成。对肾上腺皮质激素长期使用引起的肾上腺皮质功能减退有预防及对抗作用。 |
中文名 | 羟甲烯龙 |
---|---|
英文名 | oxymetholone |
中文别名 | 枸橼酸托法替尼 | 17β-羟基-2-羟亚甲基-17α-甲基-5α-雄甾(烷)-3-酮 | 2-羟亚甲基-17α-甲基-5α-雄甾(烷)-17β-醇-3-酮 | 康复龙 |
英文别名 | 更多 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 465.9±45.0 °C at 760 mmHg |
熔点 | 172-180°C |
分子式 | C21H32O3 |
分子量 | 332.477 |
闪点 | 249.7±25.2 °C |
精确质量 | 332.235138 |
PSA | 57.53000 |
LogP | 4.22 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 0.0±2.6 mmHg at 25°C |
折射率 | 1.590 |
储存条件 | 2~8°C |
分子结构 | 1、 摩尔折射率:95.89 2、 摩尔体积(m3/mol):284.2 3、 等张比容(90.2K):757.0 4、 表面张力(dyne/cm):50.3 5、 极化率(10 -24cm 3):38.01 |
更多 | 一、物性数据 性状:白色结晶性粉末,无嗅 密度(g/mL,25/4℃):不可用 相对蒸汽密度(g/mL,空气=1):不可用 熔点(ºC):173-176 沸点(ºC,常压):不可用 沸点(ºC,5.2kPa):不可用 折射率:不可用 闪点(ºC):不可用 比旋光度(º):不可用 自燃点或引燃温度(ºC):不可用 蒸气压(kPa,25ºC):不可用 饱和蒸气压(kPa,60ºC):不可用 燃烧热(KJ/mol):不可用 临界温度(ºC):不可用 临界压力(KPa):不可用 油水(辛醇/水)分配系数的对数值:不可用 爆炸上限(%,V/V):不可用 爆炸下限(%,V/V):不可用 溶解性:不溶于水,易溶于氯仿,溶于二氧六环、植物油,略溶于乙醇、乙醚 |
符号 |
GHS08 |
---|---|
信号词 | Warning |
危害声明 | H351-H361 |
警示性声明 | P281 |
个人防护装备 | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
危害码 (欧洲) | T: Toxic; |
风险声明 (欧洲) | R40 |
安全声明 (欧洲) | S53-S22-S26-S36/37/39 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
RTECS号 | BV8060000 |
海关编码 | 2937290023 |
康复龙上游产品 0 | |
---|---|
康复龙下游产品 2 | |
可用番麻皂素或剑麻皂素经乙酰化、还原、开环、氧化、水解、消除、肟化、重排、水解、加成、氧化、水解、缩合等多步反应制得该品。
海关编码 | 2937290023 |
---|
Detection of urinary metabolites common to structurally related 17alpha-alkyl anabolic steroids in horses and application to doping tests in racehorses: methandienone, methandriol, and oxymetholone.
J. Anal. Toxicol. 32(5) , 387-91, (2008) Methandienone, methandriol, and oxymetholone, which are anabolic steroids possessing 17alpha-methyl and 17beta-hydroxy groups, were developed as oral formulations for therapeutic purposes. However, th... |
|
Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature.
Br. J. Sports Med. 39(5) , e27, (2005) Anabolic androgenic steroids (AAS) are used illicitly at high doses by bodybuilders. The misuse of these drugs is associated with serious adverse effects to the liver, including cellular adenomas and ... |
|
Characterization of spontaneous and chemically induced cardiac lesions in rodent model systems: the national toxicology program experience.
Cardiovasc. Toxicol. 5(2) , 227-44, (2005) Induction of heart disease can be related to exposure to a number of agents, including environmental chemicals. Studies with laboratory rodents are commonly used to identify cardiotoxic agents and to ... |
(2Z,5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-2-(hydroxymethylene)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one |
(2Z,5α,17β)-17-hydroxy-2-(hydroxymethylidene)-17-methylandrostan-3-one |
(2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxyméthylidène)-10,13,17-triméthylhexadécahydro-3H-cyclopenta[a]phénanthrén-3-one |
MFCD00869395 |
Stanozolol impurity B |
Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5α,17β)- |
(2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one |
(2Z,5α,17β)-17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one |
2-Hydroxymethylene-17a-methyl-17b-hydroxy-5a-androstan-3-one |
Oxymetholone |
4,5a-Dihydro-2-hydroxymethylene-17a-methyltestosterone |
Raboral |
EINECS 207-098-6 |
Oximetholone |
2-Hydroxymethylene-17a-methylandrostan-17b-ol-3-one |
(2Z,5α,17β)-17-Hydroxy-2-(hydroxymethyliden)-17-methylandrostan-3-on |
Adroyd |
Anadroyd |
Anadrol |
Roboral |
Adroidin |
Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (2Z,5α,17β)- |
Becorel |
(5a,17b)-17-Hydroxy-2-(hydroxymethylene)-17-methylandrostan-3-one |
(2Z,5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-2-(hydroxymethyliden)-10,13,17-trimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-on |